OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
0 hedge funds and large institutions have $0 invested in OncoMed Pharmaceuticals, Inc. in 2019 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 41 closing their positions.
100% less funds holding
Funds holding: 41 → 0 (-41)
100% less capital invested
Capital invested by funds: $16.9M → $0 (-$16.9M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 41
Top Buyers
Top Sellers
| 1 |
Primecap Management
Pasadena,
California
|
-$5.67M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$4.27M |
| 3 |
Renaissance Technologies
New York
|
-$1.88M |
| 4 |
PA
Perceptive Advisors
New York
|
-$1.79M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$395K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$21K | -20,310 | Closed |
|
|
LWAC
27
Laurel Wealth Advisors (California)
Solana Beach,
California
| – | -$17K | -15,900 | Closed |
|
|
HCM
28
Hodges Capital Management
Dallas,
Texas
| – | -$16K | -15,592 | Closed |
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$16K | -14,993 | Closed |
|
30
Baird Financial Group
Milwaukee,
Wisconsin
| – | -$12K | -12,000 | Closed |
|
31
Two Sigma Advisers
New York
| – | -$12K | -11,300 | Closed |
|
32
State Street
Boston,
Massachusetts
| – | -$11K | -10,189 | Closed |
|
33
Wells Fargo
San Francisco,
California
| – | -$2K | -2,270 | Closed |
|
34
Fidelity Investments
Boston,
Massachusetts
| – | -$1K | -1,300 | Closed |
|
35
UBS Group
Zurich,
Switzerland
| – | -$1K | -1,200 | Closed |
|
36
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$1K | -500 | Closed |
|
OMED Hedge Fund Activity: Q2 2019 in Review
0 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q2 2019, worth a combined $0 — down 100% from $16.9M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of OMED and 0 opened new positions — a net loss of 41 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Primecap Management, exiting entirely with an estimated $5.67M sold.
- 0 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q2 2019, down from 41 in Q1 2019.
- Funds reported $0 of OncoMed Pharmaceuticals, Inc. stock for Q2 2019, down 100% quarter-over-quarter.
- 0 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q2 2019 and 41 closed out, a net change of -41 holders.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q2 2019 was Primecap Management, an estimated $5.67M sold.
Based on aggregated 13F filings for Q2 2019.